LUNG CANCER is the number one cause of cancer deaths in the United States and remains the most prevalent cancer in the western world, accounting for 33% of all cancer-related deaths. NSCLC comprises approximately 82% of all lung cancer cases. The current prognosis for subjects with NSCLC is poor. Approximately 185,000 new cases of NSCLC are expected in the United States this year. To combat NSCLC, many dedicated researches and clinicians have devoted their lives to developing effective treatments for this dreaded disease. To help accelerate the development of these therapies, qualified participants are needed to evaluate new vaccines by participating in clinical trials.
To see a list of current participating clinical sites and contact information, please visit the ClinicalTrial.gov website here. Qualified participants in this trial are provided the experimental therapeutic vaccine at no cost.
If you, or someone you know, has recently been diagnosed with non-small cell lung cancer and are interested in participating in this clinical trial, please visit the ClinicalTrial.gov website here. Once you have established contact with one of the clinical sites, a clinical professional will answer your questions, determine if you qualify for the study, and begin the enrollment process. Lucanix® currently is under clinical investigation and has not been approved for use in the United States, Canada, Europe or elsewhere. The product has not been proved to be safe or effective, and any claims of safety and effectiveness can be made only after regulatory review of the data and approval of the labeled claims. Lucanix® is a registered trademark of NovaRx.
|
